Revenue Forecast

The estimated revenue for the base year 2023 is $1,558.6 million with a CAGR of 3.4% for the study period from 2023 to 2028.

The Impact of the Top 3 Strategic Imperatives on the Global Blood Group Typing Industry

Disruptive Technologies

• Why: Disruptive technologies such as automation, robotics, and molecular blood typing are transforming the blood group typing industry by enhancing productivity and accuracy. For example, Grifos has effectively used robots to speed up blood typing procedures and sample processing. Molecular blood typing, which uses DNA analysis to determine blood type precisely, is improving compatibility matching for transplants and transfusions. Immucor is at the forefront of these innovative initiatives, which improve patient safety and precision.

• Frost Perspective: Competition and growth in blood group typing necessitate the adoption of innovative technologies. Bio-Rad Laboratories and Roche Diagnostics are exemplifying integration in molecular blood typing, crucial for transplants and transfusions, while Bio-Rad Laboratories’ automation enhances laboratory efficiency. Compliance with government regulations and training healthcare professionals are also crucial. Advanced technologies are enhancing patient treatment and driving growth.

Competitive Intensity

• Why: The blood group typing space is fiercely competitive, with multiple competitors fighting for market share. This puts pressure on prices and stimulates aggressive advertising strategies and product development strategies, as seen with the strong rivalry between Bio-Rad Laboratories and Immucor.
• Frost Perspective: Industry players need to differentiate their offerings with innovative, cost-efficient, and accurate solutions. Combining assets and expertise can be advantageous in collaborations and partnerships. Customer-centric strategies and solutions customized to meet specific end-user needs help develop a loyal customer base. Companies that manage competition well will be able to adjust to changes in the market and maximize long-term growth and success. To maintain a competitive edge and establish a solid market position, industry players must adopt strategic approaches and innovate.

Industry Convergence

• Why: Partnerships are a key trend in the blood group typing space. A notable collaboration is that between Grifos and Roche Diagnostics, which combines automation technologies with expertise in molecular blood typing. The outcome of this partnership is a comprehensive blood typing system that sets the bar for increased accuracy and efficiency in blood typing procedures by merging streamlined automation with accurate molecular analysis.
• Frost Perspective: The combination of molecular analysis, automation, and data analytics can transform the industry while boosting workflow and accuracy. Players in the industry should concentrate on R&D, adopt a holistic approach, and strive to meet changing healthcare demands and enhance patient outcomes.

Scope of the Study

• The study of blood groups and antibodies is known as immunohematology. It includes a range of blood tests, such as those that identify an individual's Rh factor and blood group.
• This study focuses on blood group typing, which is a blood group test that identifies an individual’s blood group based on the absence and presence of particular antigens on the surface of their red blood cells. The scope does not include immunohematology tests such as lymphocyte proliferation assays, flow cytometry, autoimmune disease testing, coagulation studies, and platelet function tests. However, in certain cases the study does look at the implications of market factors on the broader immunohematology sector.
• These forecasts use a qualitative approach for the growth opportunity analyses because of the industry’s private nature and lack of quantitative measures.

Test Type Segmentation

ABO Blood Test & Rh Typing

The Rh factor (+ or -) on red blood cells is identified by Rh typing, which is important for blood compatibility in transfusions and organ transplants. The ABO blood test detects the presence of A, B, AB, or O blood type antigens.

Antibody Screening

Antibody screening helps assure safe blood transfusions and reduces the chance of adverse reactions by identifying unexpected antibodies in a person's blood that may react with transfused blood.

HLA Typing

HLAs are distinct proteins on the surface of leukocytes, or white blood cells. Understanding immunological reactions and ensuring organ transplant compatibility depend on HLA typing.

Antigen Typing

The process of antigen typing involves finding particular antigens that are on the surface of red blood cells. This data is comprehensive and necessary for accurate blood matching, which is essential for safe blood transfusions.

Others

Other test types include direct antiglobulin testing (DAT), cross-matching testing, titration, Rh phenotyping, weak D/partial D determination, antibody identification, and point-of-care testing (POCT).

Competitive Environment

Key Competitors and Industry Players

• Ortho Corporation
• Grifols
• Bio-Rad Laboratories
• Werfen (Immunoc)
• Danaher Corporation
• Abbott Laboratories
• Roche Diagnostics
• DiaSorin
• Discover AliveDx (formerly Quotient)
• Siemens Healthineers
• Merck KGaA
• Fujirebio (Fujilm)
• Thermo Fisher Scientific
• F. Hoffmann-La Roche Ltd.
• biosurfit SA
• Hemogenomics
• Inno-Train Diagnostik GmbH
• Rapid Labs
• Alpha Laboratories
• Reagen LLC
• Acon Laboratories, Inc.
• Shanghai Succeed Scientific
• MAK SYSTEM S.A.
• BAG Healthcare
• J Mitra & Co. Pvt. Ltd.
• Day Medical SA
• Wadian Technologies
• Hemo Bioscience
• AXO Science
• Precision Biologic, Inc.
• Lumos Diagnostics
• Axiom Laboratories
• Other Prominent Industry Players